A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT ID: NCT00787852

Last Updated: 2014-07-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-03-31
• Study Completion Date: 2011-12-31

Brief Summary

The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and potentially resectable disease.

Detailed Description

Describe the safety of maintenance dasatinib, 100 mg/day for 2 years, in patients with stage III NSCLC.

For patients with potentially resectable disease, to assess the pathologic complete response following neoadjuvant dasatinib, paclitaxel, carboplatin and 50.4 Gy concurrent radiation.

For patients with locally unresectable disease, to obtain radiographic response data following dasatinib, paclitaxel, carboplatin and 64.8 Gy radiation.

Conditions

Non-Small Cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47

Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily

Maintenance x 2 years*

Group Type: EXPERIMENTAL

Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47

Intervention Type: DRUG

Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily

Maintenance x 2 years*

Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38

Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily Maintenance x 2 years*

Group Type: EXPERIMENTAL

Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38

Intervention Type: DRUG

Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily Maintenance x 2 years*

Interventions

Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47

Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily

Maintenance x 2 years*

Intervention Type: DRUG

Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38

Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36

Dasatinib is to be taken 1x daily

1. 50 mg daily 100 mg daily

2. 70 mg daily 100 mg daily

3. 100 mg daily 100 mg daily Maintenance x 2 years*

Intervention Type: DRUG

Other Intervention Names

Group 1: Locally Advanced Stage III NSCLC; Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC

Eligibility Criteria

Inclusion Criteria

• Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or IIIB non-small cell lung cancer; excluding patients with N3 disease based on supraclavicular or contralateral hilar adenopathy, [according to AJCC Staging, 6th edition; see Appendix G] within 4 weeks of registration.
• No prior chemotherapy or radiation for lung cancer. No prior radiation for any malignancy within the radiation field.
• Patients may be potentially resectable or unresectable.
• Stage III A or B disease, including no distant metastases- based on following diagnostic workup:

• History/physical examination prior to registration.
• CT Scan of the chest or Pet Scan within 28 days of study entry.
• CT Scan of abdomen or MRI of abdomen or Pet Scan within 28 days of study entry.
• An MRI of the brain or Head CT Scan with contrast within 28 days of study entry.
• Total body PET scan within 6 weeks of study entry is highly recommended and required for operable patients. If a PET scan is performed then a bone scan is not required.
• A bone scan should be performed within 6 weeks of study entry. A bone scan is not needed if a PET scan is performed.
• Mediastinoscopies are highly recommended. Mediastinoscopy is required for all patients not undergoing PET scans and for those who are operable.
• Patients must have measurable or evaluable disease.
• Patients with post-obstructive pneumonia are eligible.
• Patients must be at least 3 weeks from prior thoracotomy (if performed)
• ECOG Performance Status 0-1. Age > 18.
• Post-op predicted FEV1 > 40% to be eligible for surgical resection.
• CBC/differential obtained within 2 weeks prior to registration on study, with adequate bone marrow function defined as follows:

• Absolute neutrophil count (ANC) > 1,500 cells/ul.
• Platelets > 100,000 cells/ul.
• Hemoglobin > 9.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb > g/dl is acceptable.)
• PT, PTT all Grade 0-1
• Serum creatinine < 1.5 x ULN
• Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
• AST and ALT < 2.5 x the ULN
• Serum Na, K+, Mg2+, Phosphate in normal range (LLN)
• Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration.
• Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
• If you are capable of giving birth to or fathering a child, you must agree to use a form of birth control (examples of effective birth control are: a condom or a diaphragm with spermicidal jelly; oral, injectable, or implanted birth control; or abstinence) that is medically acceptable to your study doctor while taking part in this research study. This is necessary because the treatment involved in this study may be significantly teratogenic.
• PFT's within 8 weeks of study entry
• EKG within 6 weeks of study entry
• Ability to take oral medication (dasatinib must be swallowed whole)
• Patient must sign study specific informed consent prior to study entry.
• Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy (discontinue St. Johns Wort at least 5 days before starting dasatinib)

Exclusion Criteria

• Supraclavicular disease
• Pleural or pericardial effusion of any grade
• No prior malignancy [other than the one treated in this study] which required radiotherapy or systemic treatment within the past 3 years
• Severe, active co-morbidity, defined as follows:
• Cardiac Symptoms; any of the following should be considered for exclusion:

• Uncontrolled angina, congestive heart failure or MI within (6 months)
• Diagnosed congenital long QT syndrome
• Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
• Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
• Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
• Protocol-specific requirements may also exclude immuno-compromised patients
• History of significant bleeding disorder unrelated to cancer, including:
• Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease).
• Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
• Ongoing or recent (< 3 months) significant gastrointestinal bleeding
• Concomitant Medications, any of the following should be considered for exclusion:

• Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib):

1. quinidine, procainamide, disopyramide

2. amiodarone, sotalol, ibutilide, dofetilide

3. erythromycin, clarithromycin

4. chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine

• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness

• Women who:are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding
• Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin.

• Uncontrolled neuropathy grade 2 or greater regardless of cause.
• Patients who are on full dose aspirin, Clopidogrel bisulfate (plavix) or other GPIIb/IIIa platelet inhibitors are not eligible. Patients must have these agents stopped within 7 days of initiated treatment. Patients may be on low dose aspirin (81 mg/day).

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rhode Island Hospital

OTHER

Sponsor Role: collaborator

Memorial Hospital of Rhode Island

OTHER

Sponsor Role: collaborator

Brown University

OTHER

Sponsor Role: lead

Responsible Party

howard safran

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Howard Safran, md

Role: STUDY_DIRECTOR

Brown University

Locations

Lifespan Hospitals

Providence, Rhode Island, United States

Countries

United States

Other Identifiers

BrUOG-NSCL-216

Identifier Type: -

Identifier Source: org_study_id